Response to “Reply to ‘Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial’”

HR is a member of advisory boards for Gilead, AbbVie, Abbott, Merck, Janssen, Roche and VBI Vaccines. All proceeds were donated to Center for Disease Analysis Foundation. His organization has received research funding from Gilead, Assembly Biosciences, AbbVie, Boehringer Ingelheim, Intercept, Merck, Novartis, Pfizer and Roche. SB was an employee of the CDA Foundation. Otherwise, she has nothing else to declare. AB has received research funding from Gilead and Abbvie. The employer of PB has received project, research and travel grants from Abbvie and Gilead. BMüllhaupt has received speaking and/or consulting fees from Merck/MSD, AbbVie, Intercept, Astra, Bayer, BMS and Gilead Sciences and research support from Gilead Sciences. FN has served as a speaker, a consultant and an advisory board member for Gilead, AbbVie, Albireo, Genfit and Roche Diagnostics. DS has received research grants, consulting fees and/or speaker fees from AbbVie, Gilead and MSD. AS, CS and BMaeschli have no conflict of interests to declare. Data sharing is not applicable to this article as no new data were created or analyzed in this study.